Optieum Biotechnologies
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Optieum Biotechnologies - overview
Established
2020
Location
-, Ehime, Japan
Primary Industry
Biotechnology
About
Founded in 2020 and based in Toon, Japan, Optieum Biotechnologies Inc operates as a biotechnology company that uses the potential of T-cells for developing treatments for cancer and other diseases. In April 2026, Optieum Biotechnologies Inc raised an undisclosed amount in venture funding from Vision Incubate. The firm as of January 2025, is led by its President and CEO, Shun Nishioka. Optieum Biotechnologies specializes in advanced biopharmaceutical solutions, primarily focusing on optimizing CAR-T (Chimeric Antigen Receptor T-cell) therapies and addressing the critical unmet needs in oncology.
Their core offerings enhance immune responses against various cancers, providing advancements in personalized medicine. Optieum's products are utilized in clinical trials across North America and Europe, catering to healthcare providers, research institutions, and biopharmaceutical companies seeking cancer treatment options. Optieum Biotechnologies generates revenue primarily through collaborations, licensing agreements, and clinical trial partnerships with pharmaceutical companies and healthcare institutions. The company will use the April 2026 funding to accelerate clinical trial preparation for its lead CAR-T pipeline.
Current Investors
ANRI, UntroD Capital Japan, Iyogin Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.optieumbio.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.